(Q38022807)

27 August 2017

Immunotherapies for non-small-cell lung cancer and mesothelioma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6317076&resulttype=core&format=json

13 May 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6317076&resulttype=core&format=json

13 May 2020

author name string

Raffit Hassan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6317076&resulttype=core&format=json

13 May 2020

publication date

28 June 2012

1 reference

Lancet Oncology Commission

27 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6317076&resulttype=core&format=json

13 May 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6317076&resulttype=core&format=json

13 May 2020

page(s)

e301-10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6317076&resulttype=core&format=json

13 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6317076&resulttype=core&format=json

Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma

13 May 2020

cites work

1 reference

12 December 2020

Role of transforming growth factor beta in human disease

1 reference

12 December 2020

A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma

1 reference

12 December 2020

Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44

1 reference

12 December 2020

Localised spontaneous regression in mesothelioma -- possible immunological mechanism

1 reference

12 December 2020

Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis

1 reference

12 December 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

12 December 2020

T-cell regulation by CD28 and CTLA-4.

1 reference

12 December 2020

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation

1 reference

12 December 2020

Generation of dendritic cell-based vaccines for cancer therapy

1 reference

12 December 2020

Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma

1 reference

12 December 2020

Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism.

1 reference

12 December 2020

Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress

1 reference

12 December 2020

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

12 December 2020

Human DF3/MUC1 carcinoma-associated protein functions as an oncogene

1 reference

12 December 2020

Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer

1 reference

12 December 2020

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

1 reference

12 December 2020

Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents

1 reference

12 December 2020

Changing trends in US mesothelioma incidence

1 reference

12 December 2020

Characterization of effusion-infiltrating T cells: benign versus malignant effusions.

1 reference

12 December 2020

SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results

1 reference

12 December 2020

Mesothelin: a new target for immunotherapy

1 reference

12 December 2020

Toll-like receptor signalling

1 reference

12 December 2020

Cancer immunotherapy: moving beyond current vaccines

1 reference

12 December 2020

Listeria-based cancer vaccines that segregate immunogenicity from toxicity

1 reference

12 December 2020

Human lung cancer cells express functionally active Toll-like receptor 9

1 reference

12 December 2020

Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells

1 reference

12 December 2020

Dendritic cells as therapeutic vaccines against cancer

1 reference

12 December 2020

Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma

1 reference

12 December 2020

Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients

1 reference

12 December 2020

Wilms' tumour gene 1 (WT1) in human neoplasia.

1 reference

12 December 2020

Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers

1 reference

12 December 2020

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

1 reference

12 December 2020

Phase I trial of oral talactoferrin alfa in refractory solid tumors

1 reference

12 December 2020

Advances in malignant mesothelioma

1 reference

12 December 2020

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer

1 reference

12 December 2020

MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1.

1 reference

12 December 2020

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses

1 reference

12 December 2020

Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma

1 reference

12 December 2020

Therapeutic potential of Toll-like receptor 9 activation

1 reference

12 December 2020

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer

1 reference

12 December 2020

Cancer vaccines: moving beyond current paradigms

1 reference

12 December 2020

Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.

1 reference

12 December 2020

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

1 reference

12 December 2020

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

1 reference

12 December 2020

Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung

1 reference

12 December 2020

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

1 reference

12 December 2020

Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells

1 reference

12 December 2020

The use of mycobacterial adjuvant-based agents for immunotherapy of cancer

1 reference

12 December 2020

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

1 reference

12 December 2020

Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse

1 reference

12 December 2020

Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity.

1 reference

12 December 2020

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

1 reference

12 December 2020

Cancer/testis (CT) antigens: potential targets for immunotherapy

1 reference

12 December 2020

Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination

1 reference

12 December 2020

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

12 December 2020

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

1 reference

12 December 2020

TGFbeta signalling: a complex web in cancer progression

1 reference

12 December 2020

Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity

1 reference

12 December 2020

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

12 December 2020

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

1 reference

12 December 2020

Cancer statistics, 2010

1 reference

12 December 2020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

12 December 2020

Improved endpoints for cancer immunotherapy trials

1 reference

12 December 2020

A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer

1 reference

12 December 2020

Therapeutic cancer vaccines: are we there yet?

1 reference

12 December 2020

Toll-like receptor 9 agonists as cancer therapeutics

1 reference

12 December 2020

Safety of BLP25 Liposome Vaccine (L-BLP25) in Japanese Patients with Unresectable Stage III NSCLC after Primary Chemoradiotherapy: Preliminary Results from a Phase I/II Study

1 reference

12 December 2020

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer

1 reference

12 December 2020

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy

1 reference

12 December 2020

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction

1 reference

12 December 2020

Lymphocytic infiltration of pleural mesothelioma and its significance for survival

1 reference

12 December 2020

Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines

1 reference

12 December 2020

Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines

1 reference

12 December 2020

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

1 reference

12 December 2020

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

1 reference

12 December 2020

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

1 reference

12 December 2020

Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production

1 reference

12 December 2020

Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo

1 reference

12 December 2020

Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine

1 reference

12 December 2020

Sera from patients with malignant mesothelioma can contain autoantibodies.

1 reference

12 December 2020

10.1016/S1470-2045(12)70126-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6317076&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6317076&resulttype=core&format=json

13 May 2020

1 reference